Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 10/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30736968 | 0.89 | CACNA1H (0.52) | CACNA1HDRD2MEN1GAAKMT2A | |
| SCHEMBL15686293 | 0.85 | CACNA1H (0.48) | CACNA1HDRD2MEN1GAAKMT2A | |
| SCHEMBL32683928 | 0.80 | CACNA1H (0.55) | CACNA1HDRD2MEN1GAAKMT2A | |
| SCHEMBL30736966 | 0.80 | CACNA1H (0.53) | CACNA1HDRD2SIGMAR1EPHX1JAK2 | |
| SCHEMBL30737084 | 0.79 | NR1H2 (0.43) | MEN1KMT2AEPHX1ALDH1A1 | |
| SCHEMBL31465612 | 0.78 | CACNA1H (0.43) | CACNA1HDRD2MEN1GAAKMT2A | |
| SCHEMBL30737178 | 0.78 | DRD2 (0.60) | CACNA1HDRD2MEN1GAAKMT2A | |
| SCHEMBL31301242 | 0.77 | DRD2 (0.63) | CACNA1HDRD2MEN1GAAKMT2A | |
| SCHEMBL25279192 | 0.76 | CACNA1H (0.56) | CACNA1HDRD2MEN1KMT2ASIGMAR1 | |
| SCHEMBL30737230 | 0.75 | CACNA1H (0.60) | CACNA1HDRD2MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4580405-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | Oerth Bio LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050016-A9 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2024050016-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2024-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | CRBN, STUB1, CUL1 | CACNA1H 3729/4885DRD2 4665/4885MEN1 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.